The present invention provides a patch preparation comprising lidocaine or a salt thereof, lactic acid, and a hydroxy acid having 4 to 6 carbon atoms, wherein the amount of lactic acid is 0.6 to 1.2 moles per mole of lidocaine or a salt thereof with high safety which can continuously produce the therapeutic effect of lidocaine for a long time by adjusting the skin penetration rate of lidocaine to a proper range when applied to the skin and also show the similar bioequivalence to the existing preparations comprising lidocaine even when high concentration of lidocaine is used.

The present invention provides a composition for local tumescent anesthesia wherein 100 cc volume of the composition comprising 0.5-1 ml of local vasoconstrictor agent of concentration 1 mg/ml, 20-40 ml of local anesthetic agent of concentration 7.5 mg/ml; 1-2 ml of anti-fibrinolytic agent of concentration 500 mg/5 ml. The composition together generate less pain, minimize the bleeding risks and its post-operative complications, promote the tissue dissection and exerts a longer anesthetic effect. The local tumescent anesthesia composition is diluted in saline or ringer lactate solution. The composition may be employed in various surgeries selected from cosmetic surgery, plastic surgery, reconstructive surgery, head and neck surgery, ENT surgery, gynecological surgery, orthopedic surgery, proctological surgery.

The present invention provides a composition for local tumescent anesthesia wherein 100 cc volume of the composition comprising 0.5-1 ml of local vasoconstrictor agent of concentration 1 mg/ml, 20-40 ml of local anesthetic agent of concentration 7.5 mg/ml; 1-2 ml of anti-fibrinolytic agent of concentration 500 mg/5 ml. The composition together generate less pain, minimize the bleeding risks and its post-operative complications, promote the tissue dissection and exerts a longer anesthetic effect. The local tumescent anesthesia composition is diluted in saline or ringer lactate solution. The composition may be employed in various surgeries selected from cosmetic surgery, plastic surgery, reconstructive surgery, head and neck surgery, ENT surgery, gynecological surgery, orthopedic surgery, proctological surgery.

The present invention relates to the technical field of dyes for marking organic tissue. It relates to a dye whose composition contains pigments, topical anaesthetics and absorption potentiator, used to visually mark a specific area of the surface of the organic tissue and concomitantly anaesthetize the marked area. The anaesthetic dye can be applied with a pen/stick. The invention simplifies procedures that require the marking of an anaesthetized region for subsequent intervention, saving time and anaesthetic and providing greater safety for patients. A method for applying said composition is also provided.

The present invention relates to the technical field of dyes for marking organic tissue. It relates to a dye whose composition contains pigments, topical anaesthetics and absorption potentiator, used to visually mark a specific area of the surface of the organic tissue and concomitantly anaesthetize the marked area. The anaesthetic dye can be applied with a pen/stick. The invention simplifies procedures that require the marking of an anaesthetized region for subsequent intervention, saving time and anaesthetic and providing greater safety for patients. A method for applying said composition is also provided.

A medical covering film and system, and a usage method and an application therefor. The medical covering film comprises a barrier film layer (10), an adsorption layer (20), and a reticular adhesive layer (30), one side of the adsorption layer (20) being composited on the barrier film layer (10), and the reticular adhesive layer (30) being composited on the other side of the adsorption layer (20); the area of an adhesive-free region (31) of the reticular adhesive layer (30) occupies 10% or more of the total area of the reticular adhesive layer (30), but not 100%. The present medical covering film can fix a preparation to the affected skin very well, is not easily squeezed off the target skin area by external force, and can maintain the moisture in the preparation very well.

A medical covering film and system, and a usage method and an application therefor. The medical covering film comprises a barrier film layer (10), an adsorption layer (20), and a reticular adhesive layer (30), one side of the adsorption layer (20) being composited on the barrier film layer (10), and the reticular adhesive layer (30) being composited on the other side of the adsorption layer (20); the area of an adhesive-free region (31) of the reticular adhesive layer (30) occupies 10% or more of the total area of the reticular adhesive layer (30), but not 100%. The present medical covering film can fix a preparation to the affected skin very well, is not easily squeezed off the target skin area by external force, and can maintain the moisture in the preparation very well.

A bioresorbable, sustained release pharmaceutical composition comprising: 1.8 wt % to 3.0 wt % methylcellulose and 0.1 wt % to 3.0 wt % hyaluronan in the form of a gel polymer matrix, and at least one local anesthetic agent, suitably ropivacaine, which may be administered by injection.

A bioresorbable, sustained release pharmaceutical composition comprising: 1.8 wt % to 3.0 wt % methylcellulose and 0.1 wt % to 3.0 wt % hyaluronan in the form of a gel polymer matrix, and at least one local anesthetic agent, suitably ropivacaine, which may be administered by injection.

A hydrogel for in-vivo release of medication includes at least one medication, where the hydrogel includes (i) a protein-based biopolymer functionalized with a functionalisation agent that is able to form guest-host interactions with oxidized β-cyclodextrin, preferably a primary aminoalkylphenol, more preferably gelatin functionalized with tyramine (GTA) and (ii) oxidized β-cyclodextrin (oβ-CD), where the hydrogel is cross-linked via exposure to visible light in presence of a biocompatible photoinitiator, resulting in a degree of swelling in the range of 2-20 calculated as (swollen weight−dry weight)/dry weight. It further relates to a method for its preparation, as well as to a medication for treatment of musculoskeletal disorders, preferably for treatment of infection, inflammation, malignant processes, growth disorders, degenerative disorders or treatment of pain arising from (surgical treatment of) these disorders.